Entera Bio Elects New Board Member and Approves Revised Compensation Terms at Annual Meeting
ByAinvest
Sunday, Jul 20, 2025 3:11 am ET1min read
ENTX--
Additionally, shareholders ratified and approved revised compensation terms and a one-time grant of compensation for Chief Executive Officer and Director Miranda Toledano, with 19,524,783 votes for, 428,993 against, 542,191 abstentions, and 6,197,026 broker non-votes. Similar compensation proposals were approved for Chief of Research & Development Dr. Gregory Burshtein and Chief Financial Officer Dana Yaacov-Garbeli. Shareholders also ratified the company’s amended and restated compensation policy for directors and officers, and on an advisory, non-binding basis, compensation of the company’s named executive officers was approved [1].
Furthermore, shareholders approved the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as the company’s independent auditors for the fiscal year ending December 31, 2025. The vote was 26,617,578 in favor, 59,966 against, and 15,449 abstentions [1].
The election of Haya Taitel to the Board of Directors is expected to positively impact the company's governance and financial oversight. Analysts rate ENTX as a Buy with a $10.00 price target.
References:
[1] https://www.investing.com/news/sec-filings/entera-bio-shareholders-approve-board-election-and-compensation-proposals-93CH-4142570
Entera Bio elected Haya Taitel to its Board of Directors at its annual meeting, approved revised executive compensation, and ratified Kesselman & Kesselman as auditors. The election of a new board member is expected to positively impact the company's governance and financial oversight. Analysts rate ENTX as a Buy with a $10.00 price target.
Entera Bio Ltd. (NASDAQ: ENTX) held its 2025 Annual Meeting of Shareholders on Wednesday, where shareholders voted on several key proposals. The meeting saw the election of Haya Taitel to the Board of Directors for a three-year term, with 17,288,920 votes in favor, 3,069,140 against, 137,907 abstentions, and 6,197,026 broker non-votes [1].Additionally, shareholders ratified and approved revised compensation terms and a one-time grant of compensation for Chief Executive Officer and Director Miranda Toledano, with 19,524,783 votes for, 428,993 against, 542,191 abstentions, and 6,197,026 broker non-votes. Similar compensation proposals were approved for Chief of Research & Development Dr. Gregory Burshtein and Chief Financial Officer Dana Yaacov-Garbeli. Shareholders also ratified the company’s amended and restated compensation policy for directors and officers, and on an advisory, non-binding basis, compensation of the company’s named executive officers was approved [1].
Furthermore, shareholders approved the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as the company’s independent auditors for the fiscal year ending December 31, 2025. The vote was 26,617,578 in favor, 59,966 against, and 15,449 abstentions [1].
The election of Haya Taitel to the Board of Directors is expected to positively impact the company's governance and financial oversight. Analysts rate ENTX as a Buy with a $10.00 price target.
References:
[1] https://www.investing.com/news/sec-filings/entera-bio-shareholders-approve-board-election-and-compensation-proposals-93CH-4142570
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet